Immunopathogenesis of dengue hemorrhagic fever

Virology

Volumn 257, Issue 1, 1999, Pages 1-6

  Rothman, Alan L ^a   Ennis, Francis A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPILLARY LEAK SYNDROME; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; CYTOLYSIS; DENGUE; DENGUE VIRUS; FLAVIVIRUS; HYPOTHESIS; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFECTION RISK; LIVER INJURY; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTOPENIA;

EID: 0033602558     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.9656     Document Type: Article

References (60)

1. Anderson R., Wang S., Osiowy C., Issekutz A. C. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J. Virol. 71:1997;4226-4232.
2. Dengue Haemorrhagic Fever: Diagnosis, Treatment and Control. 1986;WHO, Geneva.
3. Baluna R., Vitetta E. S. Vascular leak syndrome: A side effect of immunotherapy. Immunopharmacology. 37:1997;117-132.
4. Bethell D. B., Flobbe K., Cao X. T., Day N. P., Pham T. P., Buurman W. A., Cardosa M. J., White N. J., Kwiatkowski D. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J. Infect. Dis. 177:1998;778-782.
5. Bhamarapravati N., Tuchinda P., Boonyapaknavik V. Pathology of Thailand haemorrhagic fever: A study of 100 autopsy cases. Ann. Trop. Med. Parasitol. 61:1967;500-510.
6. Bokisch V. A., Top F. H. Jr., Russell P. K., Dixon F. J., Muller-Eberhard H. J. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N. Engl. J. Med. 289:1973;996-1000.
7. +. J. Virol. 63:1989;5086-5091.
8. Burke D. S., Nisalak A., Johnson D. E., Scott R. M. A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg. 38:1988;172-180.
9. Burke-Gaffney A., Keenan A. K. Modulation of human endothelial cell permeability by combinations of the cytokines interleukin-1 alpha/beta, tumor necrosis factor-alpha and interferon-gamma. Immunopharmacology. 25:1993;1-9.
10. Cannon M. J., Openshaw P. J. M., Askonas B. A. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J. Exp. Med. 168:1988;1163-1168.
11. Chang D. M., Shaio M. F. Production of interleukin-1 (IL-1) and IL-1 inhibitor by human monocytes exposed to dengue virus. J. Infect. Dis. 170:1994;811-817.
12. Dharakul T., Kurane I., Bhamarapravati N., Yoksan S., Vaughn D. W., Hoke C. H., Ennis F. A. Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine. J. Infect. Dis. 170:1994;27-33.
13. Doherty P. C. Cytotoxic T cell effector and memory function in viral immunity. Curr. Top. Microbiol. Immunol. 206:1996;1-14.
14. +. J. Virol. 1999.
15. +. J. Virol. 70:1996;141-147.
16. Grau G. E., Heremans H., Piguet P. F., Pointaire P., Lambert P. H., Billiau A., Vassalli P. Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. Proc. Natl. Acad. Sci. USA. 86:1989;5572-5574.
17. +. J. Virol. 67:1993;5962-5967.
18. Green S., Vaughn D. W., Kalayanarooj S., Nimmannitya S., Suntayakorn S., Nisalak A., Lew R., Innis B. L., Kurane I., Rothman A. L., Ennis F. A. Early immune activation in acute dengue is related to development of plasma leakage and disease severity. J. Infect. Dis. 179:1999;755-762.
19. Gubler D. J., Suharyono W., Tan R., Abidin M., Sie A. Viraemia in patients with naturally acquired dengue infection. Bull. WHO. 59:1981;623-630.
20. Halstead S. B. Immunological parameters of togavirus disease syndromes. The Togaviruses. Biology, Structure, Replication. 1980;Academic Press, New York. p. 107-173.
21. Halstead S. B. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev. Infect. Dis. 11:1989;S830-S839.
22. Halstead S. B., Nimmannitya S., Cohen S. N. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J. Biol. Med. 42:1970;311-328.
23. Halstead S. B., O'Rourke E. J., Allison A. C. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J. Exp. Med. 146:1977;218-229.
24. Heinzel F. P. The role of IFN-gamma in the pathology of experimental endotoxemia. J. Immunol. 145:1990;2920-2924.
25. Hober D., Delannoy A. S., Benyoucef S., De Groote D., Wattre P. High levels of sTNFR p75 and TNF alpha in dengue-infected patients. Microbiol. Immunol. 40:1996a;569-573.
26. Hober D., Poli L., Roblin B., Gestas P., Chungue E., Granic G., Imbert P., Pecarere J. L., Vergez-Pascal R., Wattre P., Maniez-Montreuil M. Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in dengue-infected patients. Am. J. Trop. Med. Hyg. 48:1993;324-331.
27. Hober D., Shen L., Benyoucef S., De Groote D., Deubel V., Wattre P. Enhanced TNFα production by monocytic-like cells exposed to dengue virus antigens. Immunol. Lett. 53:1996b;115-120.
28. Kalayanarooj S., Vaughn D. W., Nimmannitya S., Green S., Suntayakorn S., Kunentrasai N., Viramitrachai W., Ratanachu-eke S., Kiatpolpoj S., Innis B. L., Rothman A. L., Nisalak A., Ennis F. A. Early clinical and laboratory indicators of acute dengue illness. J. Infect. Dis. 176:1997;313-321.
29. Klavinskis L. S., Tishon A., Oldstone M. B. A. Efficiency and effectiveness of cloned virus-specific cytotoxic T lymphocytes in vivo. J. Immunol. 143:1989;2013-2016.
30. Kliks S. C., Nimmanitya S., Nisalak A., Burke D. S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38:1988;411-419.
31. Kliks S. C., Nisalak A., Brandt W. E., Wahl L., Burke D. S. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:1989;444-451.
32. Kontny U., Kurane I., Ennis F. A. Gamma interferon augments Fc-gamma receptor-mediated dengue virus infection of human monocytic cells. J. Virol. 62:1988;3928-3933.
33. Kuno G., Bailey R. E. Cytokine responses to dengue infection among Puerto Rican patients. Mem. Inst. Oswaldo Cruz. 89:1994;179-182.
34. +-. J. Virol. 65:1991a;1823-1828.
35. Kurane I., Ennis F. A. Immunity and immunopathology in dengue virus infections. Semin. Immunol. 4:1992;121-127.
36. Kurane I., Ennis F. A. Cytokines in dengue virus infections: role of cytokines in the pathogenesis of dengue hemorrhagic fever. Semin. Virol. 5:1994;443-448.
37. Kurane I., Innis B. L., Nimmannitya S., Nisalak A., Meager A., Janus J., Ennis F. A. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J. Clin. Invest. 88:1991b;1473-1480.
38. Kurane I., Innis B. L., Nisalak A., Hoke C., Nimmannitya S., Meager A., Ennis F. A. Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production. J. Clin. Invest. 83:1989;506-513.
39. Kurane I., Meager A., Ennis F. A. Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity. J. Exp. Med. 170:1989;763-775.
40. +-. J. Gen. Virol. 76:1995;2243-2249.
41. +. J. Immunol. 154:1995;1287-1295.
42. Malasit P. Complement and dengue haemorrhagic fever/shock syndrome. SE Asian J. Trop. Med. Public Health. 18:1987;316-320.
43. Mathew A., Kurane I., Green S., Stephens H. A. F., Vaughn D. W., Kalayanarooj S., Suntayakorn S., Chandanayingyong D., Ennis F. A., Rothman A. L. Predominance of HLA-restricted CTL responses to serotype crossreactive epitopes on nonstructural proteins after natural dengue virus infections. J. Virol. 72:1998;3999-4004.
44. +. J. Clin. Invest. 98:1996;1684-1694.
45. Morens D. M. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin. Infect. Dis. 19:1994;500-512.
46. Nedwin G. E., Svedersky L. P., Bringman T. S., Palladino M. A. Jr., Goeddel D. V. Effect of interleukin 2, interferon-γ, and mitogens on the production of tumor necrosis factors α and β J. Immunol. 135:1985;2492-2497.
47. Nimmannitya S. Clinical spectrum and management of dengue haemorrhagic fever. SE Asian J. Trop. Med. Pub. Health. 18:1987;392-397.
48. Rico-Hesse R., Harrison L. M., Nisalak A., Vaughn D. W., Kalayanarooj S., Green S., Rothman A. L., Ennis F. A. Molecular evolution of dengue type 2 virus in Thailand. Am. J. Trop. Med. Hyg. 58:1998;96-101.
49. Rico-Hesse R., Harrison L. M., Salas R. A., Tovar D., Nisalak A., Ramos C., Boshell J., Mesa M. T. R. d., Nogueira R. M. R., Rosa A. T. d. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology. 230:1997;244-251.
50. Rothman A. L. Pathogenesis of dengue virus infection. Rose B. D. Up To Date in Infectious Diseases. 1999;UpToDate, Wellesley.
51. Ruangjirachuporn W., Boonpucknavig S., Nimmanitya S. Circulating immune complexes in serum from patients with dengue haemorrhagic fever. Clin. Exp. Immunol. 36:1979;46-53.
52. Sangkawibha N., Rojanasuphot S., Ahandrik S., Viriyapongse S., Jatanasen S., Salitul V., Phanthumachinda B., Halstead S. B. Risk factors for dengue shock syndrome: A prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am. J. Epidemiol. 120:1984;653-669.
53. Scott R. M., Nisalak A., Cheamudon U., Seridhoranakhul S., Nimmannitya S. Isolation of dengue viruses from peripheral blood leukocytes of patients with hemorrhagic fever. J. Infect. Dis. 141:1980;1-6.
54. Shaio M. F., Cheng S. N., Yuh Y. S., Yang K. D. Cytotoxic factors released by dengue virus-infected human blood monocytes. J. Med. Virol. 46:1995;216-223.
55. Sobel A. T., Bokisch V. A., Muller-Eberhard H. J. C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum. J. Exp. Med. 142:1975;139-150.
56. Stolpen A. H., Guinan E. C., Fiers W., Pober J. S. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am. J. Pathol. 123:1986;16-24.
57. Thein S., Aung M. M., Shwe T. N., Aye M., Zaw A., Aye K., Aye K. M., Aaskov J. Risk factors in dengue shock syndrome. Am. J. Trop. Med. Hyg. 56:1997;566-572.
58. Theofilopoulos A. N., Wilson C. B., Dixon F. J. The Raji cell radioimmune assay for detecting immune complexes in human sera. J. Clin. Invest. 57:1976;169-182.
59. Thijs L. G., Hack C. E., Strack van Schijndel R. J. M., Nuijens J. H., Wolbink G. J., Eerenberg-Belmer A. J. M., van der Vall H., Wagstaff J. Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J. Immunol. 144:1990;2419-2424.
60. Tracey K. J., Cerami A. Tumor necrosis factor, other cytokines and disease. Annu. Rev. Cell Biol. 9:1993;317-343.